☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) (Exact name of Registrant as specified in its charter) Israel 98-1704718 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition pe ...

Exhibit 99.1 Turning Point Brands Announces Fourth Quarter and Full Year 2025 Results LOUISVILLE, KY – March 2, 2026 – Turning Point Brands, Inc. ("TPB" or "the Company") (NYSE: TPB), a manufacturer, marketer and distributor of branded consumer products, including alternative smoking accessories and consumables with active ingredients, today announced financial results for the fourth quarter and full year ended December 31, 2025. Q4 2025 vs. Q4 2024 FY 2025 vs. FY 2024 Graham Purdy, President and CEO, comme ...

Market Opportunity - Zusduri has an estimated total addressable market opportunity of over $5.0 billion for recurrent low-grade intermediate risk NMIBC, with an annual treatable population of approximately 82,000 in the U.S.[511] Clinical Trial Results - The CR rate for Zusduri in the ENVISION trial was 79.6% at three months, with 60.8% of all enrolled patients in CR at 12 months[526] - Jelmyto achieved a CR rate of 58% in the Olympus trial, with a durability of response estimated at 81.8% at 12 months[518] - The ENVISION trial demonstrated a 72.2% DOR at 24 months for patients who achieved CR at three months[528] - In the Phase 3 ENVISION trial, 78% of patients achieved complete response (CR) at three months, with 79% of those maintaining CR at 12 months[531] - The Phase 3b study showed that 75% of patients achieved CR after home administration of Zusduri, with six out of eight patients completing all six instillations[530] - The median duration of response for patients achieving CR with Jelmyto was not reached, with a median follow-up of 28.1 months[519] - The median duration of response (DOR) for patients in the OPTIMA II trial was 24.2 months, with a median follow-up of 35.8 months[529] - The UTOPIA trial for UGN-103 enrolled 99 patients globally, with a three-month CR rate of 77.8%[536] Regulatory Approvals - The FDA approved Zusduri on June 12, 2025, for the treatment of adults with recurrent low-grade intermediate risk NMIBC[523] - The FDA approved Zusduri on June 12, 2025, based on data from 223 patients in the ENVISION trial[531] - Jelmyto's new product exclusivity expired on April 15, 2023, but Orphan Drug exclusivity extends until April 15, 2027[515] - Medicare has established a permanent J-code for Jelmyto effective January 1, 2021, and granted it a New Technology APC effective October 1, 2023[522] Financial Performance - The company recognized $109.8 million in revenue for the year ended December 31, 2025, compared to $90.4 million in 2024, reflecting a 21.5% increase[551] - Revenue for the year ended December 31, 2025, was $109.8 million, an increase of $19.4 million from $90.4 million in 2024, primarily driven by sales of Zusduri and increased sales of Jelmyto[574] - Net cash used in operating activities increased to $162.4 million for the year ended December 31, 2025, compared to $96.8 million in 2024, primarily due to higher operating expenses[600] - The net loss for the year ended December 31, 2025, was $153.5 million, compared to a net loss of $126.9 million in 2024, reflecting an increase of $26.6 million[573] Research and Development - Research and development expenses totaled $67.1 million in 2025, up from $57.1 million in 2024, indicating a 17.5% increase[555] - The company anticipates continued increases in research and development expenses as clinical programs progress and additional product candidates are developed[558] - Research and development expenses rose to $67.1 million in 2025 from $57.1 million in 2024, an increase of $10.0 million attributed to higher manufacturing costs for Zusduri and costs associated with clinical trials[576] Marketing and Sales - Selling and marketing expenses increased to $99.1 million in 2025 from $75.2 million in 2024, reflecting a rise of $23.9 million due to commercial activities for Zusduri and expanded sales operations[577] - The company initiated a strategic promotion of Zusduri in the U.S. in late June 2025, achieving open access for over 95% of covered lives[533] Cash and Financing - As of December 31, 2025, the company had $120.5 million in cash and cash equivalents and marketable securities[582] - Financing activities provided net cash of $39.9 million in 2025, a decrease of $154.7 million from $194.6 million in 2024, mainly due to reduced proceeds from share issuances[602] - The company expects to finance future cash needs through a combination of equity offerings, debt financings, and collaborations, with no assurance of securing additional financing on favorable terms[605][606] - UroGen Pharma, Inc. entered into a Securities Purchase Agreement on July 26, 2023, resulting in gross proceeds of $120.0 million from the sale of 12,579,156 ordinary shares[593] - The company completed a public offering on June 20, 2024, raising gross proceeds of $107.5 million from the sale of 5,000,000 ordinary shares[594] Tax and Accounting - The company has approximately $626.7 million in carry forward tax losses as of December 31, 2025, and does not expect to pay taxes in Israel until taxable income is generated[571] - Deferred income tax assets and liabilities are determined based on differences between financial reporting and tax bases, using currently enacted tax rates[625] - The company follows a two-step approach in recognizing uncertain tax positions, measuring benefits based on cumulative probability[626] Currency and Inflation - The company experienced a 12.5% depreciation of the U.S. dollar against the NIS during 2025, which could adversely affect dollar-denominated results of operations[629] - Inflation did not have a material effect on the company's business or financial condition during the year ended December 31, 2025[628] - The company does not currently engage in currency hedging activities but may consider using foreign currency forward and swap contracts in the future to manage currency risks[630] Share-Based Compensation - The company recognizes share-based compensation costs over the requisite service period, with performance-based awards expensed when achievement of performance criteria is probable[622] Long-Term Liabilities - The company has a long-term liability recognized under the RTW Transaction, which supports the launch of Jelmyto and development of Zusduri, with future cash payments based on net sales[624] Lease Obligations - The company has a total obligation for future minimum lease payments of $4.1 million and $5.9 million under operating and finance leases, respectively, as of December 31, 2025[611]

Exhibit 99.1 UroGen Announces ZUSDURITM Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results PRINCETON, N.J. March 2, 2026-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided an overview of recent developments. "2025 was a tremendously successful and transform ...

FOR IMMEDIATE RELEASE Monday, March 2, 2026 FOURTH QUARTER FINANCIAL HIGHLIGHTS: All Year-Over-Year Comparisons Unless Otherwise Noted: TEGNA Inc. Reports Fourth Quarter and Full-Year 2025 Results Achieves or exceeds all previously announced full-year 2025 guidance metrics On track to complete proposed acquisition by Nexstar Media Group by the second half of 2026, subject to regulatory approvals and customary closing conditions McLean, Va. – TEGNA Inc. (NYSE: TGNA) today announced financial results for the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of e ...

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2026 BIOATLA, INC. (Exact name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K 11085 Torreyana Road San Diego, California 92121 (Address of Principal Executive Offices) (Zip Code) Delaware 001-39787 85-1922320 (Commission File Number) (IRS ...

Exhibit 99.1 NEW YORK, March 2, 2026 /PRNewswire/ -- WhiteHorse Finance, Inc. ("WhiteHorse Finance" or the "Company") (Nasdaq: WHF) today announced its fourth quarter and full year financial results for the year ended December 31, 2025. In addition, the Company's board of directors has declared a distribution of $0.25 per share with respect to the quarter ending March 31, 2026 and a supplemental distribution of $0.01 per share. Both distributions will be payable on April 6, 2026 to stockholders of record as ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36294 uniQure N.V. (Exact name of Registrant as specified in its charter) The Netherlands (Jurisdiction of incorpor ...

Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR Delaware 36-4883909 (State or other jurisdiction of incorporation or organization) 1560 Trapelo Road Waltham, Massachusetts 02451 (Address of principal executive offices) (Zip Code) (I.R.S. Employer Identification No.) Registrant's telephone number, including area code: (781) 786-8230 ...